Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?
PubMed 文献 · Blood Adv · 2018-01-01
This article has a companion Counterpoint by Moskowitz.
原文
This article has a companion Counterpoint by Moskowitz.
来源:Blood Adv,查看原文。版权归原作者所有。
引用
- Peggs KS. Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT? Blood Adv. 2018. PMID: 29636327. doi:10.1182/bloodadvances.2017011122
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。